Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldberg, J. M.
Right arrow Articles by Recio, F. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldberg, J. M.
Right arrow Articles by Recio, F. O.

Annals of Surgical Oncology, Vol 5, Issue 5 399-406, Copyright © 1998 by Society of Surgical Oncology

ARTICLES

Improvements in pelvic exenteration: factors responsible for reducing morbidity and mortality

J. M. Goldberg, M. S. Piver, R. E. Hempling, C. Aiduk, L. Blumenson and F. O. Recio
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.

BACKGROUND: Since pelvic exenteration for the treatment of recurrent gynecologic malignancy first was described, reported rates of morbidity and mortality have declined steadily. However, the factors responsible for this decline have never been clearly delineated. METHODS: We reviewed the charts of 154 patients who underwent pelvic exenteration for gynecologic malignancy between 1954 and 1994. Charts were abstracted for details of the surgical procedure, pathologic findings, postoperative management, short- and long-term complications, time to recurrence, and overall survival. RESULTS: Seventy-two patients (47%) experienced 95 identifiable postoperative complications, resulting in death in 22 patients (14%). The rate of infectious complications declined to a statistically significant degree between the first two decades and latter two decades of the study (odds ratio [OR] 0.28. 95% CI 0.11-0.69). The use of routine prophylactic antibiotics was associated with this decline in infectious complications (OR 0.25, 95% CI 0.07-0.83). The use of preoperative subcutaneous heparin was associated with a reduction in thrombotic complications from 5 of 100 patients to 0 of 54 patients (P = .11), as well as a significant reduction in overall risk of complications (OR 0.53, 95% CI 0.33-0.85) and risk of postoperative mortality (OR 0.19, 95% CI 0.05-0.80). There was a significant reduction in overall risk of postoperative complications with both intensive care unit monitoring postoperatively (OR 0.65, 95% CI 0.43-0.99) and routine postoperative monitoring with a pulmonary artery catheter (OR 0.61, 95% CI 0.38-0.98). CONCLUSIONS: Routine use of prophylactic antibiotics, prophylactic subcutaneous heparin, and intensive postoperative monitoring appear to have reduced morbidity from pelvic exenteration.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
O. Turrini, J. Guiramand, V. Moutardier, F. Viret, D. Mokart, A. Madroszyk, B. Lelong, T. Bege, J.-L. Blache, G. Houvenaeghel, et al.
Perineal Small Bowel Fistula After Pelvic Exenteration for Cancer: Technical Guidelines for Perineal Fistula
Ann. Surg. Oncol., December 1, 2006; 13(12): 1622 - 1626.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. M. Pawlik, J. M. Skibber, and M. A. Rodriguez-Bigas
Pelvic Exenteration for Advanced Pelvic Malignancies
Ann. Surg. Oncol., May 1, 2006; 13(5): 612 - 623.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society of Surgical Oncology.